Jeff Huber
Managing Director at Triatomic Capital | Founding CEO of GRAIL | Former SVP of Google Ads, Apps, Maps & [x]
San Francisco Bay Area
Invests in
Sectors:
Locations:
Min Investment:
$250,000.00Max Investment:
$25,000,000.00Target Investment:
$10,000,000.00
Skills
Education
- Uo
- HB
Lists including Jeff
Investments
Betteromics
Total Funding: $20M
Chemify
Total Funding: $46M
Arsenal Bio
Total Funding: $220
Manifold Bio
Total Funding: $45M
Synapticure
Total Funding: $16M
Weta Digital
Total Funding: $10M
Cellanome
Total Funding: $5M
Aldevron
Total Funding: $250M
DeepSight
Total Funding: $10M
Agoric
Total Funding: $36M
Mammoth Biosciences
Total Funding: $260M
BitPay
Total Funding: $60M
LytEn
Total Funding: $10M
GRAIL
Total Funding: $240M
iMicrobes
Total Funding: $120K
Razorpay
Total Funding: $740M
Superhuman
Total Funding: $110M
UXPin
Total Funding: $2.7M
Work Experience
2022
Co-Founder & Managing Director
2022
‘Applied AI’ in Deep tech, Health tech, & New economy // Helping great entrepreneurs build 'century-defining' businesses & technologies.
Board of Directors member (public)
2024
Bringing ivonescimab – a novel, first-in-class bi-specific antibody combining immunotherapy via PD-1 blockade and anti-angiogenesis via blocking VEGF in a single molecule – quickly and responsibly to clinical deployment, to help change cancer outcomes for millions of patients.
2024
Board of Directors member
2024
d-Matrix powers next generation compute for generative AI and large language models.
2022
Board of Directors member
2022
Manifold Bio is a next-generation protein therapeutics company pioneering an in-vivo biologics design platform.
2022
Board of Directors member
2022
A new AI social platform where you can create, share, and interact with Al bots live with friends.
2021
Board of Directors member (public)
2021
Upstart's mission is to enable effortless credit based on true risk, enabled by AI/ML.
2020
Board of Directors member
2020
Mammoth Biosciences is building the CRISPR platform for the next generation of therapeutics and cell/gene therapies.
2018
Board of Directors member
2018
Openwater is creating a new generation of imaging technologies to change how we read and write our bodies and brains.
2019
Chairman / Board of Directors member
2019
Genalyte is a healthcare analytics & diagnostics company improving patient outcomes with real-time point-of-care results.
2009
Board of Directors member (public)
2009
Member of Nomination & Governance (2010-2012) and Audit (2012-present) Committees. Helped focus EA’s transition from retail to online/cloud & mobile delivery. Valuation increased >800% over tenure.